Mammary Cell News 8.27 July 14, 2016 | |
| |
TOP STORYAdaptive Randomization of Neratinib in Early Breast Cancer The I-SPY 2 trial, a multicenter, adaptive Phase II trial of neoadjuvant therapy for high-risk clinical stage II or III breast cancer, evaluated multiple new agents added to standard chemotherapy to assess the effects on rates of pathological complete response. [N Engl J Med] Abstract 1 | Abstract 2 | Press Release | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)LABORATORY RESEARCHERRα Mediates Metabolic Adaptations Driving Lapatinib Resistance in Breast Cancer Scientists report that lapatinib induced the degradation of the nuclear receptor estrogen-related receptor α (ERRα), a master regulator of cellular metabolism, and that the expression of ERRα is restored in lapatinib-resistant breast cancer cells through reactivation of mTOR signaling. [Nat Commun] Full Article Using patient biopsies and preclinical models of breast cancer, investigators demonstrate that the janus kinases (JAK)/signal transducer and activator of transcription (STAT) pathway is active in metastasis. Unexpectedly, blocking the pathway with JAK inhibitors enhanced the metastatic burden in experimental and orthotopic models of breast cancer metastasis. [Nat Commun] Full Article The authors investigated the role of microRNAs as therapeutic approach to inhibit PDGFRβ-mediated vasculogenic properties of triple negative breast cancer, focusing on miR-9 and miR-200. [Cancer Res] Abstract | Full Article Functional analysis for one of these newly identified partners revealed a noncanonical mechanism of extracellular signal–regulated kinase activation that is specific to the ERBB2:ERBB3 heterodimer and acts through the adaptor protein FAM59A in breast cancer cells. [Sci Signal] Abstract | Press Release Investigators found that TRIM28 is highly expressed in both cancer cell lines and advanced breast cancer tissues, and the levels of TRIM28 and TWIST1 are positively correlated with the aggressiveness of breast carcinomas. [Sci Rep] Full Article The Role of Membrane ERα Signaling in Bone and Other Major Estrogen Responsive Tissues To elucidate the significance, in vivo, of membrane estrogen receptor α (ERα) signaling in multiple estrogen-responsive tissues, researchers used female mice lacking the ability to localize ERα to the membrane due to a point mutation in the palmitoylation site, so called Nuclear-Only-ER mice. [Sci Rep] Full Article Because phosphatases regulate the function of kinase signaling pathways scientists investigated whether phosphatases are also differentially expressed in estrogen receptor (ER)-negative compared to those in ER-positive breast cancers. [Breast Cancer Res Treat] Full Article Using a mammary stromal cell line derived from healthy tissue subjected to long-term culture in low or high glucose, researchers found that the hyperglycemic condition favors the establishment of a pro-inflammatory and pro-oxidant environment characterized by the induction of the COX-2/PGE2 axis. [J Cell Biochem] Abstract Investigators hypothesized that obesity-related molecular networks, which normally help in cellular and organismal survival under metabolic challenges, may help in the survival of SUM149 triple-negative inflammatory breast cancer cell line (SUM149-MA) cells. The fat mass and obesity-associated protein FTO is overexpressed in SUM149-MA cells. [PLoS One] Full Article CLINICAL RESEARCHScientists determined whether the non-canonical NF-κB pathway, is activated in estrogen receptor positive breast cancer, to identify any correlation between its activity and the clinico-pathological phenotype and to explore whether NF-κB2 and RelB subunits and/or any of their target genes might be used as a predictive marker. [Br J Cancer] Abstract | |
| |
REVIEWSThe Anti-Metastatic Micro-Environment of the Bone: Importance of Osteocyte Cx43 Hemichannels Bone metastases of tumor cells are a common and life-threatening feature of a variety of late-stage cancers, including breast cancers. However, until now, much less has been known about the intrinsic anti-metastatic properties of the bones and how these could be exploited to prevent or treat bone metastases. [Biochim Biophys Acta] Abstract Visit our reviews page to see a complete list of reviews in the mammary cell research field.
| |
INDUSTRY NEWSLilly and Boehringer Ingelheim Announce Clinical Trial Collaboration in Metastatic Breast Cancer Eli Lilly and Company and Boehringer Ingelheim announced a new collaboration on a Phase Ib study that will evaluate the safety and tolerability of abemaciclib, Lilly’s cyclin-dependent kinase (CDK) 4 and CDK 6 inhibitor, in combination with BI 836845, Boehringer Ingelheim’s insulin-like growth factor (IGF)-1/IGF-2 ligand neutralizing antibody, in patients diagnosed with HR+, HER2- metastatic breast cancer. [Eli Lilly and Company] Press Release Sorrento Therapeutics, Inc. announced a license and collaboration agreement for the development, manufacture and commercialization of products using Sorrento’s fully human immuno-oncology anti-PD-1 monoclonal antibody STI-A1110. [Sorrento Therapeutics, Inc.] Press Release | |
From our sponsor: Looking for ALDH+ cancer stem cells? Watch a video to see how ALDEFLUOR™ can help.
| |
POLICY NEWSPolicy Implications of Aging in the NIH-Funded Workforce Because of national interest in the “graying” of the biomedical workforce, the authors examine aging and funding within the pool of NIH-funded investigators and applicants, particularly in the growing field of stem cell research. They provide evidence of a maturing and more competitive stem cell workforce and discuss policy implications. [Cell Stem Cell] Editorial FDA Should Stand Firm on Stem-Cell Treatments You may have heard that regulators in the United States are too strict when it comes to stem-cell treatments. The assumption in these accusations — that these treatments work — is at the heart of the problem. The FDA is right to insist that only proper clinical trials can make that case. [Nature News] Editorial House Panel Would Give NIH a 4% Raise to $33 Billion The National Institutes of Health (NIH) is slated to receive a $1.25 billion increase, to $33.3 billion, in a proposed spending measure released by a House of Representatives spending panel. That 4% boost is good news for an agency that has been flat funded for a decade, although it falls short of a 6% raise approved by a Senate panel. [ScienceInsider] Editorial | Press Release Canada’s Health Funder Agrees to Meet with Researchers Outraged by Peer-Review Changes Canadian Institute of Health Research (CIHR) President Alain Beaudet said the agency will heed Jane Philpott’s request to “convene a working meeting in the very near future with key representatives of the research community, including those who have raised this issue publicly, to find common ground and move forward with solutions that address the issues raised with regard to the quality and integrity of CIHR’s peer review system.” [ScienceInsider] Editorial U.K. Research Charity Will Self-Publish Results from Its Grantees Starting sometime this fall, the Wellcome Trust will launch its own open-access online journal. Publication will be limited to the thousands of scientists worldwide working on research funded by a Wellcome grant, and it will be free not only for readers, but authors—the charity is covering the costs charged by the company that will provide the journal’s software and online platform. [ScienceInsider] Editorial Beat It, Impact Factor! Publishing Elite Turns against Controversial Metric A paper posted to the preprint server bioRxiv, authored by senior employees at several leading science publishers (including Nature’s owner, SpringerNature), calls on journals to downplay the figure in favor of a metric that captures the range of citations that a journal’s articles attract. [Nature News] Editorial | Article Brexit Watch: Scientists Grapple with the Fallout Two weeks after the United Kingdom voted to leave the European Union, the future remains opaque. Concerns within the research community are particularly intense for those who rely on the EU for funding, or who have the right to work in the United Kingdom only because they are citizens of other EU countries. [Nature News] Editorial The Past, Present and Future of the PhD Thesis According to one of those often-quoted statistics that should be true but probably isn’t, the average number of people who read a PhD thesis all the way through is 1.6. And that includes the author. More interesting might be the average number of PhD theses that the typical scientist — and reader of Nature — has read from start to finish. [Nature News] Editorial Major Funders Launch International Repository of Cutting-Edge Cancer Models U.S. and European funding agencies are launching the Human Cancer Models Initiative, which aims to give the research community tumor cells that behave more like actual human tumors. [ScienceInsider] Editorial Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry Direct-to-consumer marketing of unapproved stem cell interventions is a well-known phenomenon in countries with lax medical regulations. However, an examination of Internet-based marketing claims revealed widespread promotion of such interventions by businesses based in the United States. Such commercial activity suggests that regulatory agencies must better oversee this marketplace. [Cell Stem Cell] Editorial
| |
EVENTSNEW 4th International Oncology Conference Visit our events page to see a complete list of events in the mammary cell community.
| |
JOB OPPORTUNITIESNEW Scientific Director – Oncology (Merck) Postdoctoral Fellow – Various Projects (National University of Singapore) Postdoctoral Fellow – Breast Cancer Monitoring through Digital Imaging (University Rovira i Virgili) Postdoctoral Researcher – Basic & Translational Breast Cancer Research (Northwestern University) Postdoctoral Associate – Premalignant Progression to Invasive Breast Cancer (Tulane Medical School) Postdoctoral Fellow – Molecular Genetics of Breast Cancer (German Cancer Research Centre) Postdoctoral Fellowship – Cancer Research (German Cancer Research Center) Postdoctoral Fellow – Proteogenomic Bioinformatics of Breast Cancer (Lund University) Postdoctoral Fellow – Cancer Biology (Hamad bin Khalifa University) PhD Fellow – Small X-Ray Angle for Breast Cancer Diagnosis (CEA Tech) Manager – Medical and Breast Imaging (Fred Hutchinson Cancer Research Center) Director Clinical Research – Medical Oncology (Fred Hutchinson Cancer Research Center) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Mammary Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|
Home Mammary Cell News Volume 8.27 | Jul 14 2016